{"filing":{"accession_number":"0001104659-26-096510","cik":"0001649989","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-12","primary_document":"tm2622399d2_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926096510/tm2622399d2_8k.htm"},"events":[{"id":27773,"run_id":25347,"accession_number":"0001104659-26-096510","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Outlook Therapeutics entered into an underwriting agreement on August 12, 2026 for a public offering of 55,555,556 shares of common stock and accompanying warrants at $0.99 per share, with estimated gross proceeds of approximately $55.0 million. This is a registered public offering of equity securities that will dilute existing shareholders, fitting the dilutive_issuance category. While technically a registered offering (not unregistered), the core event—issuance of a substantial number of new equity securities to raise capital—aligns with the dilutive_issuance taxonomy, which captures material equity capital raises at small- and mid-cap issuers.","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29441,"accession_number":"0001104659-26-096510","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Outlook Therapeutics entered into an underwriting agreement on August 12, 2026 for a public offering of 55,555,556 shares of common stock and accompanying warrants at $0.99 per share, with estimated gross proceeds of approximately $55.0 million. This is a registered public offering of equity securities that will dilute existing shareholders, fitting the dilutive_issuance category. While technically a registered offering (not unregistered), the core event—issuance of a substantial number of new equity securities to raise capital—aligns with the dilutive_issuance taxonomy, which captures material equity capital raises at small- and mid-cap issuers.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:37:38.358579+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29441,"accession_number":"0001104659-26-096510","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Outlook Therapeutics entered into an underwriting agreement on August 12, 2026 for a public offering of 55,555,556 shares of common stock and accompanying warrants at $0.99 per share, with estimated gross proceeds of approximately $55.0 million. This is a registered public offering of equity securities that will dilute existing shareholders, fitting the dilutive_issuance category. While technically a registered offering (not unregistered), the core event—issuance of a substantial number of new equity securities to raise capital—aligns with the dilutive_issuance taxonomy, which captures material equity capital raises at small- and mid-cap issuers.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:37:38.358579+00:00","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-08-14"}]}